Matinas BioPharma Holdings Inc. [MTNB] stock is down -4.63 while the S&P 500 has fallen -0.48% on Tuesday, 11/17/20. While at the time of this article, MTNB ATR is sitting at 0.05, with the beta value at 2.77. This stock’s volatility for the past week remained at 5.10%, while it was 5.78% for the past 30-day period. MTNB has fallen -$0.04 from the previous closing price of $0.80 on volume of 3.44 million shares.

On 6, November 2020, Matinas BioPharma Reports Third Quarter 2020 Financial Results and Operational Highlights. According to news published on Yahoo Finance, EnACT study of MAT2203 in cryptococcal meningitis received unanimous Data and Safety Monitoring Board (DSMB) recommendation to proceed into second patient cohort.

Analyst Birdseye View:

The most recent analyst activity for Matinas BioPharma Holdings Inc. [AMEX:MTNB] stock was on January 27, 2020, when it was Initiated with an Overweight rating from Piper Sandler, which also raised its 12-month price target on the stock to $3. On January 24, 2020, SunTrust Initiated a Buy rating. On January 23, 2020, SunTrust Initiated a Buy rating. On January 09, 2020, Aegis Capital Initiated a Buy rating and increased its price target to $3.50. On June 26, 2019, H.C. Wainwright Initiated a Buy rating and boosted its amount on this stock to $4.

In the past 52 weeks of trading, this stock has oscillated between a low of $0.49 and a peak of $2.49. Right now, according to Wall Street analyst the average 12-month amount target is $3.38. At the most recent market close, shares of Matinas BioPharma Holdings Inc. [AMEX:MTNB] were valued at $0.76.


This publicly-traded organization’s revenue is $4,277 per employee, while its income is -$827,269 per employee. Continuing to look at profitability, this corporation’s Return on Assets, Equity, Whole Principal & invested Principal is sitting at -57.73, -70.63, -70.32 and -65.49 respectively.

If looking now at the Principal structure of this organization, it shows its whole liability to the whole Principal at 11.34 and the whole liability to whole assets at 10.51. It shows enduring liability to the whole principal at 10.06 and enduring liability to assets at 0.09 while looking for an extended time period.

Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 0.7288 points at 1st support level, the second support level is making up to 0.6977. But as of 1st resistance point, this stock is sitting at 0.7923 and at 0.8247 for 2nd resistance point.

Matinas BioPharma Holdings Inc. [MTNB] reported its earnings at -$0.03 per share in the fiscal quarter closing of 9/29/2020. The Analysts for Wall Street were expecting to report its earnings at -$0.03/share signifying the difference of 0 and 0.00% surprise value. Comparing the previous quarter ending of 6/29/2020, the stated earnings were -$0.03 calling estimates for -$0.03/share with the difference of 0 depicting the surprise of 0.00%.

Important Ratio’s To Watch

Meanwhile, turning our focus to liquidity, the Current Ratio for Matinas BioPharma Holdings Inc. [AMEX:MTNB] is 23.00. Likewise, the Quick ratio is also the same, showing Cash ratio at 9.05. Now if looking for a valuation of this stock’s amount to sales ratio it’s 3,669.81 and it’s amount to book ratio is 12.74.

Insider Stories

The most recent insider trade was by STERN ADAM K, Director, and it was the purchase of 20000.0 shares on Aug 21.